Skip to main content
Fig. 8 | BMC Cancer

Fig. 8

From: Wogonin as a targeted therapeutic agent for EBV (+) lymphoma cells involved in LMP1/NF-κB/miR-155/PU.1 pathway

Fig. 8

The molecular mechanism of wogonin on LMP1/NF-κB/miRNA-155/PU.1 pathway. LMP1 protein is consisted of TM1-6, CTAR1-2 and -H2N and activates IkBα by TRAF6. P65, which is binding to IkBα, is then free from IkBα and goes into the nucleus to bind on miRNA-155 promoter, inducing over-expression of miR-155. MiR-155 prevents the transcription of PU.1, and then suppresses the apoptosis of B lymphoma cells. Wogonin inhibited the pathway by suppressing p65

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us